GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (BSP:VRTX34) » Definitions » Credit Losses Provision

Vertex Pharmaceuticals (BSP:VRTX34) Credit Losses Provision


View and export this data going back to 2019. Start your Free Trial

What is Vertex Pharmaceuticals Credit Losses Provision?

Credit Losses Provision only applies to banks.


Vertex Pharmaceuticals (BSP:VRTX34) Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.